| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 0.0 | 0.0 | 21.2 |
| Other income | 0.0 | 1.5 | 1.9 |
| Total income | 0.0 | 1.5 | 23.1 |
| Profit before exceptional items & tax | -49.9 | 1.4 | 2.5 |
| Profit before tax | -49.9 | 1.4 | 2.5 |
| Net profit | -49.9 | 1.1 | 2.5 |
| Operating margin | 0.0% | 93.3% | 10.8% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
BSE results filing, NSE: WELCURE. Figures extracted from the filing.
Welcure Drugs & Pharmaceuticals Ltd: key numbers
- Share price
- ₹0.20
- Market cap
- ₹24.72 Cr
- Revenue (annual)
- ₹365.5 Cr
- Net profit (annual)
- ₹-5.49 Cr
- P/E (TTM)
- -1.4×Sector 47.4×
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Welcure Drugs & Pharmaceuticals Ltd
All →Welcure Drugs & Pharmaceuticals Board Meeting Outcome
Welcure Drugs & Pharmaceuticals approved the closure of its Ahmedabad corporate office. Operations will continue uninterrupted with records transferred to the registered office.
Welcure Drugs & Pharmaceuticals Other Announcement
Welcure Drugs submitted its Annual Secretarial Compliance Report for FY2026 under Regulation 24A. The report confirms overall compliance while noting historical fines paid for earlier procedural delays.
Welcure Drugs & Pharmaceuticals Financial Results
Welcure Drugs and Pharmaceuticals reported annual total income of ₹367.00 Crore for FY26. The Board approved audited results, showing a net annual loss of ₹5.49 Crore.
- Value
- ₹367.0 Cr
Welcure Drugs & Pharmaceuticals Board Meeting Date
Welcure Drugs scheduled a board meeting for May 29, 2026. Directors will consider and approve audited financial results for the 2026 fiscal year.
Welcure Drugs & Pharmaceuticals Debt & Borrowing
Welcure Drugs & Pharmaceuticals Ltd confirmed it does not meet SEBI's 'Large Corporate' criteria for the financial year ended March 31, 2026. Consequently, the company is exempt from mandatory incremental borrowing through debt securities. Its outstanding borrowings as of the reporting date were nil.
Welcure Drugs & Pharmaceuticals Other Announcement
Welcure Drugs & Pharmaceuticals Ltd submitted its Regulation 74(5) certificate for the quarter and year ended March 31, 2026. The registrar, Skyline Financial Services, confirmed that no physical share certificates were received for dematerialization during this period. This is a routine regulatory disclosure with no impact on business operations.